Safety of rivaroxaban in patients with non-valvular atrial fibrillation to prevent stroke and systemic embolism

Trial Profile

Safety of rivaroxaban in patients with non-valvular atrial fibrillation to prevent stroke and systemic embolism

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 May 2015

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Embolism; Stroke
  • Focus Adverse reactions
  • Most Recent Events

    • 20 May 2015 New trial record
    • 15 May 2015 Results presented at the American Geriatrics Society 2015 Annual Scientific Meeting, according to a Janssen Pharmaceuticals media release.
    • 15 May 2015 Results published in a Janssen Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top